Arija Brize

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

Bradley J. Monk, Andrés Poveda, Ignace Vergote et al. · The Lancet Oncology · 2014 · 305 citations

Medicine, Oncology, Pharmacology +15

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

Adam Brufsky, Vicente Valero, B. Tiangco et al. · Breast Cancer Research and Treatment · 2012 · 127 citations

Medicine, Oncology, Pharmacology +12

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer

Cora N. Sternberg, Andrew J. Armstrong, Siobhan Ng et al. · Journal of Clinical Oncology · 2016 · 101 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2

Bradley J. Monk, Andrés Poveda, Ignace Vergote et al. · Gynecologic Oncology · 2016 · 96 citations · Full text

Medicine, Gynecology, Oncology +17

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Suresh S. Ramalingam, Jeffrey Crawford, Alex Y. Chang et al. · Annals of Oncology · 2013 · 56 citations · Full text

Medicine, Oncology, Pharmacology +9